Cancer

Can injectable peptides enable the growth of cancer? Some people claim so, but here are some research studies that show just the opposite:

AOD-9604 / HGH Frag 176-191 — Loaded into nanoparticles with chemo, the peptide made doxorubicin more effective at killing breast cancer cells. https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/

BPC-157 — In vitro, BPC-157 stopped human melanoma cell growth and reduced VEGF signaling. https://journals.lww.com/melanomaresearch/citation/2004/08000/bpc_157_inhibits_cell_growth_and_vegf_signalling.50.aspx

BPC-157 — In mice with colon cancer cachexia, BPC-157 reduced muscle wasting and prolonged survival. https://pubmed.ncbi.nlm.nih.gov/29898649/

DSIP — Mice injected monthly with DSIP had a 2.6-fold drop in spontaneous tumors and lived 24% longer. https://pubmed.ncbi.nlm.nih.gov/12782416/

Epitalon — Lifelong dosing in mice cut leukemia development by 6-fold. https://pubmed.ncbi.nlm.nih.gov/14501183/

Epitalon — In HER-2/neu mice, Epitalon reduced tumor number, tumor size, and lung metastasis. https://pubmed.ncbi.nlm.nih.gov/12209581/

Epitalon — Cut chemically induced colon tumors in rats from 4.1 per animal down to 2.7. https://pubmed.ncbi.nlm.nih.gov/12049808/

Follistatin 344 — In mice with ovarian cancer, follistatin prevented malignant ascites and extended survival when paired with chemo. https://pmc.ncbi.nlm.nih.gov/articles/PMC9633376/

GHK-Cu — Reversed 70% of overexpressed genes in metastatic colon cancer and activated 6 of 12 cell-death genes. https://neoplasiaresearch.com/index.php/jao/article/view/217

GHK-Cu — Modulated cancer-related gene expression in breast and prostate cancer cell lines. https://www.lidsen.com/journals/genetics/genetics-05-02-128

Kisspeptin — Restoring KISS-1 expression in human melanoma cells suppressed metastasis by 50 to 95%. https://pubmed.ncbi.nlm.nih.gov/8944003/

Kisspeptin — Inhibited tumor growth and reduced lung metastasis in mice through the EIF2AK2 pathway. https://pubmed.ncbi.nlm.nih.gov/28944853/

KPV — Mice with colitis-induced colon cancer drinking KPV-laced water had smaller tumors and fewer of them. https://pmc.ncbi.nlm.nih.gov/articles/PMC4957955/

LL-37 — Triggered programmed death of colon cancer cells. Mice without LL-37 grew significantly more tumors. https://pmc.ncbi.nlm.nih.gov/articles/PMC3910284/

LL-37 (FK-16 fragment) — Killed colon cancer cells through both apoptosis and pro-death autophagy. https://pmc.ncbi.nlm.nih.gov/articles/PMC3659029/

Melanotan 2 — Topical MT-II shrank established melanomas in mice to half the control size over 10 days. https://pmc.ncbi.nlm.nih.gov/articles/PMC7013727/

MOTS-c — Low MOTS-c predicted worse survival in ovarian cancer patients. Giving MOTS-c blocked tumor growth in mice. https://pmc.ncbi.nlm.nih.gov/articles/PMC11578304/

Retatrutide — In obese mice, retatrutide produced a 14-fold drop in pancreatic tumor size and a 17-fold drop in lung tumor size. https://pmc.ncbi.nlm.nih.gov/articles/PMC11908972/

Semaglutide — Across 1.65 million patients, GLP-1 users had lower rates of 10 of 13 obesity-related cancers vs insulin users. https://pmc.ncbi.nlm.nih.gov/articles/PMC11227080/

Semaglutide — A Scandinavian cohort of 145,000 patients showed no increased thyroid cancer risk. https://pubmed.ncbi.nlm.nih.gov/38683947/

Semaglutide — Reduced colorectal, liver, and pancreatic cancer rates vs DPP-4 inhibitors. https://pmc.ncbi.nlm.nih.gov/articles/PMC12587238/

SS-31 — Protected mice on chemo from mitochondrial damage and muscle loss without blocking the chemo's anti-tumor effect. https://pmc.ncbi.nlm.nih.gov/articles/PMC7923037/

Thymalin — Lowered spontaneous tumor rates and extended lifespan in mice. https://pubmed.ncbi.nlm.nih.gov/6752596/

Thymalin — Arrested or shrank transplanted sarcomas in over half the rats it was given to. https://pubmed.ncbi.nlm.nih.gov/29797130/

Thymosin Alpha-1 — In 56 advanced lung cancer patients, Thymosin Alpha-1 paired with chemo extended median survival to 12.6 months. https://pubmed.ncbi.nlm.nih.gov/8652276/

Thymosin Alpha-1 — In a randomized HCC trial, more patients on Thymosin Alpha-1 became eligible for liver transplant. https://pmc.ncbi.nlm.nih.gov/articles/PMC2748379/

Thymosin Alpha-1 — Added to chemo in 488 stage 4 melanoma patients, it improved tumor response and survival. https://pubmed.ncbi.nlm.nih.gov/20194853/

Thymosin Alpha-1 — In 146 patients after liver cancer surgery, it improved recurrence-free and overall survival. https://pubmed.ncbi.nlm.nih.gov/27900029/

Thymosin Alpha-1 — Pretreatment before checkpoint inhibitors extended overall survival in melanoma patients. https://pubmed.ncbi.nlm.nih.gov/30063847/

Tirzepatide — In obese mice with triple-negative breast cancer, tirzepatide suppressed tumor growth. https://www.biorxiv.org/content/10.1101/2024.01.20.576484v1

Tirzepatide — Restored anti-tumor immunity in an obesity-driven colon cancer model. https://aacrjournals.org/cancerres/article/84/6_Supplement/2188/738498/Abstract-2188-Tirzepatide-treatment-restores

VIP — Increased programmed death of liver cancer cells by hitting the cAMP/Bcl-xL pathway. https://pmc.ncbi.nlm.nih.gov/articles/PMC6317926/